This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.
Demethylation of the miR-146a promoter by 5-Aza-2’-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer
Androgen deprivation therapy is the primary strategy for the treatment of advanced prostate cancer; however, after an initial regression, most patients will inevitably develop a fatal androgen-independent tumo...
Citation: BMC Cancer 2014 14:308